Ascletis Pharma Inc (F:2VJ) — Market Cap & Net Worth
Market Cap & Net Worth: Ascletis Pharma Inc (2VJ)
Ascletis Pharma Inc (F:2VJ) has a market capitalization of $1.26 Billion (€1.08 Billion) as of August 6, 2026. Listed on the F stock exchange, this Germany-based company holds position #7883 globally and #1065 in its home market, demonstrating a 3.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ascletis Pharma Inc's stock price €1.02 by its total outstanding shares 1055344320 (1.06 Billion). Review Ascletis Pharma Inc balance sheet liabilities to assess the company's total debt and financial obligations.
Ascletis Pharma Inc Market Cap History: 2018 to 2026
Ascletis Pharma Inc's market capitalization history from 2018 to 2026. Data shows change from $760.03 Million to $1.26 Billion (-1.49% CAGR).
Ascletis Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ascletis Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
730.06x
Ascletis Pharma Inc's market cap is 730.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $760.03 Million | $166.32 Million | -$7.26 Million | 4.57x | N/A |
| 2019 | $402.22 Million | $173.44 Million | -$95.97 Million | 2.32x | N/A |
| 2020 | $355.34 Million | $35.00 Million | -$209.24 Million | 10.15x | N/A |
| 2021 | $407.16 Million | $76.88 Million | -$199.02 Million | 5.30x | N/A |
| 2022 | $666.26 Million | $54.09 Million | -$314.84 Million | 12.32x | N/A |
| 2023 | $177.67 Million | $56.60 Million | -$144.72 Million | 3.14x | N/A |
| 2024 | $424.43 Million | $1.28 Million | -$300.94 Million | 330.81x | N/A |
| 2025 | $1.48 Billion | $2.03 Million | -$359.88 Million | 730.06x | N/A |
Competitor Companies of 2VJ by Market Capitalization
Companies near Ascletis Pharma Inc in the global market cap rankings as of August 6, 2026.
Key companies related to Ascletis Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #544 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #569 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $478.71 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $760.66 |
| #544 | Argen-X | BR:ARGX | $49.55 Billion | €728.00 |
| #569 | UCB SA | BR:UCB | $47.34 Billion | €223.30 |
Ascletis Pharma Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Ascletis Pharma Inc's market cap moved from $760.03 Million to $ 1.26 Billion, with a yearly change of -1.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.26 Billion | -15.00% |
| 2025 | €1.48 Billion | +248.84% |
| 2024 | €424.43 Million | +138.89% |
| 2023 | €177.67 Million | -73.33% |
| 2022 | €666.26 Million | +63.64% |
| 2021 | €407.16 Million | +14.58% |
| 2020 | €355.34 Million | -11.66% |
| 2019 | €402.22 Million | -47.08% |
| 2018 | €760.03 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 5th, 2026 the market cap of Ascletis Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.26 Billion USD |
| MoneyControl | $1.26 Billion USD |
| MarketWatch | $1.26 Billion USD |
| marketcap.company | $1.26 Billion USD |
| Reuters | $1.26 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory … Read more